FDA Postmarketing Active Surveillance Pilot To Study Adverse Event Signals
This article was originally published in The Gray Sheet
Executive Summary
FDA has issued a request for proposals for an active postmarketing surveillance pilot program to evaluate adverse event signals that may be linked to medical devices or drugs.